What happened
Reassessing galectin inhibition: Lessons for context-selective drug design and translational oncology
SourceElsevier BVpublicationBiotech
Reassessing galectin inhibition: Lessons for context-selective drug design and translational oncology
Publication signal: Reassessing galectin inhibition: Lessons for context-selective drug design and translational oncology
Factual summary
Why it matters
Recent source-backed research output for AISci Stage A browsing.
SourceElsevier BVLimitations
AISci rank score does not assess scientific quality or citation impact.
SourceElsevier BVLinked output
Reassessing galectin inhibition: Lessons for context-selective drug design and translational oncologypaperPeople
No reviewed person relationship is attached to this event.
Organizations
No reviewed organization relationship is attached to this event.
Topics
Problems
No reviewed problem relationship is attached to this event.
Relationship evidence
Protein and Drug Design
Controlled AISci Stage A topic for Protein and Drug Design.
Reassessing galectin inhibition: Lessons for context-selective drug design and translational oncology
Reassessing galectin inhibition: Lessons for context-selective drug design and translational oncology
Timeline
- publicationReassessing galectin inhibition: Lessons for context-selective drug design and translational oncology